Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Antonio Palumbo, Massimo Offidani, Francesca Patriarca, Maria Teresa Petrucci & Michele Cavo. (2015) Bendamustine for the treatment of multiple myeloma in first-line and relapsed–refractory settings: a review of clinical trial data. Leukemia & Lymphoma 56:3, pages 559-567.
Read now
Read now
Massimo Gentile, Anna Grazia Recchia, Carla Mazzone, Ernesto Vigna, Massimo Martino, Lucio Morabito, Eugenio Lucia, Sabrina Bossio, Laura De Stefano, Teresa Granata, Angela Palummo & Fortunato Morabito. (2013) An old drug with a new future: bendamustine in multiple myeloma. Expert Opinion on Pharmacotherapy 14:16, pages 2263-2280.
Read now
Read now
Anna Korycka-Wołowiec & Tadeusz Robak. (2012) Pharmacokinetic evaluation and therapeutic activity of bendamustine in B-cell lymphoid malignancies. Expert Opinion on Drug Metabolism & Toxicology 8:11, pages 1455-1468.
Read now
Read now
G. Damaj, F. Malard, C. Hulin, D. Caillot, R. Garidi, B. Royer, G. Marit, A.M. Stoppa, A. Banos, N. Morineau, P. Moreau, O. Fitoussi, M. Tiab & P. Moreau. (2012) Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukemia & Lymphoma 53:4, pages 632-634.
Read now
Read now
Marco Montillo, Francesca Ricci, Alessandra Tedeschi, Eleonora Vismara & Enrica Morra. (2010) Bendamustine: new perspective for an old drug in lymphoproliferative disorders. Expert Review of Hematology 3:2, pages 131-148.
Read now
Read now
Morie A. Gertz. (2007) What is the correct philosophy for the treatment of multiple myeloma?. Leukemia & Lymphoma 48:12, pages 2298-2299.
Read now
Read now
Articles from other publishers (31)
Bruno Almeida Costa, Tarek H. Mouhieddine, Ricardo J. Ortiz & Joshua Richter. (2023) Revisiting the role of alkylating agents in multiple myeloma: Up-to-date evidence and future perspectives. Critical Reviews in Oncology/Hematology 187, pages 104040.
Crossref
Crossref
Alexandra Gomez-Arteaga, Tomer M. Mark, Danielle Guarneri, Paul J. Christos, Usama Gergis, June D. Greenberg, Jingmei Hsu, Sebastian A. Mayer, Ruben Niesvizky, Roger N. Pearse, Adrienne A. Phillips, Adriana Rossi, Morton Coleman, Koen van Besien & Tsiporah B. Shore. (2019) High-dose bendamustine and melphalan conditioning for autologous stem cell transplantation for patients with multiple myeloma. Bone Marrow Transplantation 54:12, pages 2027-2038.
Crossref
Crossref
Jesus G. Berdeja, Todd Bauer, Edward Arrowsmith, James Essell, Patrick Murphy, James A. ReevesJrJr, Ralph V. Boccia, William Donnellan & Ian Flinn. (2017) Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy. British Journal of Haematology 177:2, pages 254-262.
Crossref
Crossref
Iris Breitkreutz, Natalia Becker, Axel. Benner, Florentina Kosely, Christoph Heining, Jens Hillengass, Gerlinde Egerer, Anthony D. Ho, Hartmut Goldschmidt & Marc S. Raab. (2016) Dose-intensified bendamustine followed by autologous peripheral blood stem cell support in relapsed and refractory multiple myeloma with impaired bone marrow function. Hematological Oncology 34:4, pages 200-207.
Crossref
Crossref
Claudio Cerchione, Davide Nappi, Maria Di Perna, Irene Zacheo, Anna Emanuele Pareto, Marco Picardi, Lucio Catalano & Fabrizio Pane. (2016) Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma. Case Reports in Hematology 2016, pages 1-3.
Crossref
Crossref
Massimo Gentile, Ernesto Vigna, Anna Grazia Recchia, Lucio Morabito, Francesco Mendicino, Giovanna Giagnuolo & Fortunato Morabito. (2015) Bendamustine in multiple myeloma. European Journal of Haematology 95:5, pages 377-388.
Crossref
Crossref
I-Jun Lau, Dean Smith, Robin Aitchison, Norbert Blesing, Pamela Roberts, Andrew Peniket, Kwee Yong, Neil Rabin & Karthik Ramasamy. (2014) Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and/or refractory to bortezomib and lenalidomide. Annals of Hematology 94:4, pages 643-649.
Crossref
Crossref
Albert Oriol & Cristina Motlló. (2014) Nuevos fármacos en el tratamiento del mieloma múltiple. Medicina Clínica 143:6, pages 268-274.
Crossref
Crossref
Yong Wang, Ruirui Zhu, Yongnian Ni & Serge Kokot. (2014) Competitive interactions of anti-carcinogens with serum albumin: A spectroscopic study of bendamustine and dexamethasone with the aid of chemometrics. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 123, pages 241-248.
Crossref
Crossref
G. Pratt, S. Bowcock, M. Lai, S. Bell, J. Bird, S. D'Sa, J. Cavenagh, G. Cook, G. Morgan, R. Owen, J.A. Snowden, K. Yong & F. Davies. (2014) United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma. International Journal of Laboratory Hematology 36:1, pages 20-28.
Crossref
Crossref
M Offidani, L Corvatta, L Maracci, A M Liberati, S Ballanti, I Attolico, P Caraffa, F Alesiani, T Caravita di Toritto, S Gentili, P Tosi, M Brunori, D Derudas, A Ledda, A Gozzetti, C Cellini, L Malerba, A Mele, A Andriani, S Galimberti, P Mondello, S Pulini, U Coppetelli, P Fraticelli, A Olivieri & P Leoni. (2013) Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study. Blood Cancer Journal 3:11, pages e162-e162.
Crossref
Crossref
Wolfram Pönisch, Malvina Bourgeois, Barbara Moll, Simone Heyn, Nadja Jäkel, Ina Wagner, Robert Rohrberg, Hans-Jürgen Hurtz, Marion Schmalfeld, Michael Aßmann, Thomas Edelmann, Martin Mohren, Franz Albert Hoffmann, Cornelia Becker, Andreas Schwarzer, Uta Schönfelder, Thomas Zehrfeld, Gerald Hensel, Kerstin Löschcke, Rainer Krahl, Haifa Al Ali & Dietger Niederwieser. (2012) Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma. Journal of Cancer Research and Clinical Oncology 139:3, pages 499-508.
Crossref
Crossref
James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel‐Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward J. Gorak, Youram Nassir, Regina A. Swift & Debra Mayo. (2012)
Phase
I
/
II
trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma
. British Journal of Haematology 160:3, pages 321-330.
Crossref
Crossref
Heinz Ludwig & Peter Sonneveld. (2012) Disease control in patients with relapsed and/or refractory multiple myeloma: what is the optimal duration of therapy?. Leukemia Research 36, pages S27-S34.
Crossref
Crossref
Suzanne Lentzsch, Amy O'Sullivan, Ryan C. Kennedy, Mohammad Abbas, Lijun Dai, Silvana Lalo Pregja, Steve Burt, Michael Boyiadzis, G. David Roodman, Markus Y. Mapara, Mounzer Agha, John Waas, Yongli Shuai, Daniel Normolle & Jeffrey A. Zonder. (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119:20, pages 4608-4613.
Crossref
Crossref
Nathan FowlerBrad S. KahlPeter LeeJeffrey V. MatousAmanda F. CashenSamuel A. JacobsJeffrey LetzerBipinkumar AminMichael E. WilliamsSonali SmithAlfred SalehPeter RosenHongliang ShiSudha ParasuramanBruce D. Cheson. (2011) Bortezomib, Bendamustine, and Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma: The Phase II VERTICAL Study. Journal of Clinical Oncology 29:25, pages 3389-3395.
Crossref
Crossref
Niels W.C.J. van de Donk, Henk M. Lokhorst, Meletios Dimopoulos, Michele Cavo, Gareth Morgan, Hermann Einsele, Martin Kropff, Steve Schey, Hervé Avet-Loiseau, Heinz Ludwig, Hartmut Goldschmidt, Pieter Sonneveld, Hans E. Johnsen, Joan Bladé, Jesús F. San-Miguel & Antonio Palumbo. (2011) Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treatment Reviews 37:4, pages 266-283.
Crossref
Crossref
Meletios A. Dimopoulos, Jesus F. San-Miguel & Kenneth C. Anderson. (2011) Emerging therapies for the treatment of relapsed or refractory multiple myeloma. European Journal of Haematology 86:1, pages 1-15.
Crossref
Crossref
Jatin J. Shah & Robert Z. Orlowski. 2011. Bortezomib in the Treatment of Multiple Myeloma. Bortezomib in the Treatment of Multiple Myeloma
79
94
.
Kevin D. Boyd, Faith E. Davies & Gareth J. Morgan. 2011. Multiple Myeloma. Multiple Myeloma
151
187
.
Thomas Moehler & Hartmut Goldschmidt. 2011. Multiple Myeloma. Multiple Myeloma
239
271
.
P. Moreau & C. Hulin. (2010) Les nouveaux médicaments du myélomeNovel agents in the treatment of multiple myeloma. Oncologie 12:5-6, pages 353-361.
Crossref
Crossref
M. Kropff & W.E. Berdel. (2010) Therapieoptionen im Rezidiv des multiplen MyelomsTherapy options for recurrent multiple myeloma. Der Onkologe 16:3, pages 282-288.
Crossref
Crossref
Bruce D. Cheson, Clemens-Martin Wendtner, Angelika Pieper, Martin Dreyling, Jonathan Friedberg, Dieter Hoelzer, Philippe Moreau, John Gribben, Stefan Knop, Marco Montillo & Mathias Rummel. (2010) Optimal Use of Bendamustine in Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphomas, and Multiple Myeloma: Treatment Recommendations From an International Consensus Panel. Clinical Lymphoma Myeloma and Leukemia 10:1, pages 21-27.
Crossref
Crossref
M Michael, I Bruns, E Bölke, F Zohren, A Czibere, N N Safaian, F Neumann, R Haas, G Kobbe & R Fenk. (2010) Bendamustine in patients with relapsed or refractory multiple myeloma. European Journal of Medical Research 15:1, pages 13.
Crossref
Crossref
Ashley E. Glode & Anthony JarkowskiIIIIII. (2012) Bendamustine: A New Treatment Option for Chronic Lymphocytic Leukemia. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29:11, pages 1375-1384.
Crossref
Crossref
Efstathios Kastritis, Antonio Palumbo & Meletios A. Dimopoulos. (2009) Treatment of Relapsed/Refractory Multiple Myeloma. Seminars in Hematology 46:2, pages 143-157.
Crossref
Crossref
Bruce D. Cheson & Mathias J. Rummel. (2009) Bendamustine: Rebirth of an Old Drug. Journal of Clinical Oncology 27:9, pages 1492-1501.
Crossref
Crossref
Joseph R. Mikhael, Andrew R. Belch, H. Miles Prince, Maria Nambo Lucio, Angelo Maiolino, Alessandro Corso, Maria Teresa Petrucci, Pellegrino Musto, Mieczyslaw Komarnicki & A. Keith Stewart. (2009) High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program. British Journal of Haematology 144:2, pages 169-175.
Crossref
Crossref
Trevor W. Dennie & Jill M. Kolesar. (2009) Bendamustine for the treatment of chronic lymphocytic leukemia and rituximab-refractory, indolent B-cell non-hodgkin lymphoma. Clinical Therapeutics 31, pages 2290-2311.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:3, pages 184-191.
Crossref
Crossref